Compare DFLI & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFLI | CING |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8M | 64.5M |
| IPO Year | 2021 | 2021 |
| Metric | DFLI | CING |
|---|---|---|
| Price | $1.09 | $5.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.25 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 353.0K | 146.1K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,630,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $51.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 15.77 | N/A |
| 52 Week Low | $0.26 | $3.16 |
| 52 Week High | $5.15 | $11.89 |
| Indicator | DFLI | CING |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 55.62 |
| Support Level | $1.10 | $4.76 |
| Resistance Level | $1.46 | $5.54 |
| Average True Range (ATR) | 0.06 | 0.31 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 17.39 | 56.06 |
Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.